Angela Barone Selected Research

3- (5- methyl- 2- (2- oxo- 1,2- dihydroindol- 3- ylidenemethyl)- 1H- pyrrol- 3- yl)propionic acid

5/2006

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Angela Barone Research Topics

Disease

3	Neoplasms (Cancer) 01/2020 - 05/2006
1	Non-alcoholic Fatty Liver Disease 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Dysbiosis 01/2021
1	Carcinoma (Carcinomatosis) 01/2020

Drug/Important Bio-Agent (IBA)

1	mastihaIBA 01/2021
1	IronIBA 01/2021
1	LipidsIBA 01/2021
1	sialyl-lactotetraosylceramideIBA 01/2020
1	GlycosphingolipidsIBA 01/2020
1	GangliosidesIBA 08/2015
1	Phosphotransferases (Kinase)IBA 05/2006
1	3- (5- methyl- 2- (2- oxo- 1,2- dihydroindol- 3- ylidenemethyl)- 1H- pyrrol- 3- yl)propionic acidIBA 05/2006
1	Imatinib Mesylate (Gleevec)FDA Link 05/2006
1	Sunitinib (Sutent)FDA Link 05/2006
1	Platelet-Derived Growth FactorIBA 05/2006
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 05/2006
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2006
1	tyrosine receptor (receptor, tyrosine)IBA 05/2006